Ocular Bioavailability

ocular bioavailability

Ocular bioavailability means how much of a drug or other substance actually reaches the tissues inside the eye and can do its job after you take it. It covers not just how much of the substance gets to the eye, but also how long it stays there and whether it reaches the specific part of the eye that needs treatment. The eye is protected by several barriers, like the cornea, tear film, and special blood vessels, so many medicines struggle to reach their target. Different ways of giving a treatment — eyedrops, injections into the eye, or pills taken by mouth — lead to very different levels of ocular bioavailability. If a medicine has low ocular bioavailability, doctors may need higher doses or special delivery methods to make it work. Measuring this helps researchers design drugs that cross the right barriers and reach the retina or other delicate eye structures. Understanding ocular bioavailability also matters for safety, because drugs that reach the eye in high amounts can cause side effects there. It influences the choice between local treatments that act directly on the eye and systemic treatments that affect the whole body. Scientists work on ways to improve ocular bioavailability with formulations, nanoparticles, or controlled-release devices so treatments can be more effective and have fewer side effects. In short, ocular bioavailability is a key concept for making eye medicines that actually get to the right place in the eye and help patients.